Azadeh Moghaddas1, Mohammad Adib-Majlesi1, Ali M Sabzghabaee1, Ali Hajigholami2, Rachel Riechelmann3. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. 2. Department of Internal Medicine, Haematology Section, Isfahan University of Medical Sciences, Isfahan, Iran. 3. Department of Radiology and Oncology, Instituto do Cancer do Estado de Sao Paulo, São Paulo, Brazil.
Abstract
INTRODUCTION: Patients suffering from solid tumors use a wide range of cytotoxic drugs. In this study, we aimed to detect, document, and descriptively analyze the potential drug-drug interactions in hospitalized solid tumor's patients in a Middle Eastern referral oncology-hematology University-affiliated hospital. MATERIALS AND METHODS: In this cross-sectional study, the medical record of solid tumor's patients who were admitted to the referral oncological center in Isfahan, Iran, during the six months period (2018) were considered. We included all patients who had received at least two chemotherapy or nonchemotherapy drugs simultaneously. The potential drug-drug interactions between chemotherapy and nonchemotherapy drugs were evaluated with Lexi-Interact ver.1.1 online software. RESULTS: During the study period, a total of 141 cancer patients were recruited, and their drug therapy regiment was thoroughly analyzed. We detected 227 drug-drug interactions with moderate or major severity out of included patients in which 96, 71, 32, and 28 interactions were in the category of C, D, B, and X, respectively. One hundred and fourteen patients (80.8%) encountered at least one potential drug-drug interactions during their hospitalization. Mechanistically, most of drug-drug interactions (56.4%) were pharmacodynamics. Interaction between granisetron and metoclopramide were the top 10 detected interaction (11.4%). The interaction between docetaxel and carboplatin was the most frequent drug-drug interactions between oncology drugs (2.6% of total drug-drug interactions). CONCLUSION: Potentially moderate or major drug-drug interactions frequently occur among solid tumor's cancer patients necessitate the establishment of a clinical pharmacy service for providing relevant pharmacotherapy consultations to prevent this potentially serious concern.
INTRODUCTION:Patients suffering from solid tumors use a wide range of cytotoxic drugs. In this study, we aimed to detect, document, and descriptively analyze the potential drug-drug interactions in hospitalized solid tumor's patients in a Middle Eastern referral oncology-hematology University-affiliated hospital. MATERIALS AND METHODS: In this cross-sectional study, the medical record of solid tumor's patients who were admitted to the referral oncological center in Isfahan, Iran, during the six months period (2018) were considered. We included all patients who had received at least two chemotherapy or nonchemotherapy drugs simultaneously. The potential drug-drug interactions between chemotherapy and nonchemotherapy drugs were evaluated with Lexi-Interact ver.1.1 online software. RESULTS: During the study period, a total of 141 cancerpatients were recruited, and their drug therapy regiment was thoroughly analyzed. We detected 227 drug-drug interactions with moderate or major severity out of included patients in which 96, 71, 32, and 28 interactions were in the category of C, D, B, and X, respectively. One hundred and fourteen patients (80.8%) encountered at least one potential drug-drug interactions during their hospitalization. Mechanistically, most of drug-drug interactions (56.4%) were pharmacodynamics. Interaction between granisetron and metoclopramide were the top 10 detected interaction (11.4%). The interaction between docetaxel and carboplatin was the most frequent drug-drug interactions between oncology drugs (2.6% of total drug-drug interactions). CONCLUSION: Potentially moderate or major drug-drug interactions frequently occur among solid tumor's cancerpatients necessitate the establishment of a clinical pharmacy service for providing relevant pharmacotherapy consultations to prevent this potentially serious concern.
Authors: Amer A Koni; Maisa A Nazzal; Bushra A Suwan; Samah S Sobuh; Najiya T Abuhazeem; Asil N Salman; Husam T Salameh; Riad Amer; Sa'ed H Zyoud Journal: BMC Cancer Date: 2022-05-14 Impact factor: 4.638
Authors: Ana Isabel Gago-Sánchez; Pilar Font; Manuel Cárdenas; María Dolores Aumente; José Ramón Del Prado; Miguel Ángel Calleja Journal: Pharmacol Res Perspect Date: 2021-12
Authors: Mansoor-Ali Vaali-Mohammed; Maha-Hamadien Abdulla; Sabine Matou-Nasri; Wagdy M Eldehna; M Meeramaideen; Eslam B Elkaeed; Mohammed El-Watidy; Noura S Alhassan; Khayal Alkhaya; Omar Al Obeed Journal: Front Pharmacol Date: 2022-08-15 Impact factor: 5.988